98%
921
2 minutes
20
Background: Integrated chronic disease treatment models that enable patient self-care and shared treatment decision making have recently been shown to improve medication adherence and outcomes. Smartphone applications (apps) are a readily available means to enable this model, although sustained user engagement remains a challenge.
Objective: To assess the efficacy of improving asthma control using a proactive smartphone app without required regular inputs.
Methods: We designed a minimally intrusive smartphone app to provide individualized and timely support to patients with asthma based on the National Asthma Education and Prevention Program guidelines and Scripps management pathways. In this proof-of-concept study, we enrolled 60 adults with poorly controlled asthma to test the usability and effectiveness of this app over a 4-month period. The Asthma Control Test survey was used to assess control before, during, and after app use. As a corollary, a retrospective chart review was also used to assess changes in lung function and prescribed courses of systemic corticosteroids.
Results: Our patients, with a mean age of 50 years, reported an improvement in Asthma Control Test scores from 16.6 (inadequate to poor) to 20.5 (controlled) over the study period. Concurrently, there was a 7.9% absolute increase in FEV1, while courses of systemic corticosteroids decreased from 0.5 to 0.3 courses per 6-month period. Fifty-eight of 60 patients completed the final survey, with high satisfaction reported.
Conclusions: This app improved asthma control in a cohort of patients with uncontrolled asthma (age range, 17-82 years), while minimizing burdensome inputs and proactively providing individualized teaching and treatment support. The app and treatment model are scalable to cost-effectively manage chronic disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501988 | PMC |
http://dx.doi.org/10.1016/j.jaip.2016.03.005 | DOI Listing |
J Eval Clin Pract
September 2025
Pediatric Allergy and Immunology Department, Akdeniz University Hospital, Akdeniz University, Antalya, Türkiye.
Aims And Objectives: To evaluate the efficacy of YoungAsthma, a nurse-led, web-based mHealth intervention on asthma control and self-efficacy among adolescents with asthma utilizing decision tree analysis.
Background: Asthma is a prevalent chronic condition in pediatric populations, necessitating sustained management for optimal disease control.
Design: A randomized controlled clinical trial.
Rhinology
September 2025
Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium.
Background: Criteria for biologic treatment of uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) differ across international recommendations and prescription of biologics depends on national reimbursement criteria. CHRINOSOR offers an opportunity to analyse biologic indications in the real-world setting according to international recommendations.
Methods: CRSwNP patients who received dupilumab treatment in the ENT clinic of 6 tertiary centres (5 countries) were included.
ERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.
ERJ Open Res
September 2025
Department of Physical Therapy, School of Medicine, University of São Paulo, São Paulo, Brazil.
Background: Previous studies have shown that increasing physical activity in daily life (PADL) improves asthma clinical control and quality of life. However, the minimal clinically important difference (MCID) to promote those improvements remains unclear. The aim of this study was to estimate the MCID for PADL in people with moderate-to-severe asthma.
View Article and Find Full Text PDFJ Asthma Allergy
September 2025
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University Kyoto, Kyoto, Japan.
Background And Purpose: Biologics are crucial for severe asthma treatment, but their high costs pose challenges. Omalizumab (OML) is dosed on the basis of patient-specific factors. The purpose of this study is to clarify the clinical characteristics of severe asthmatics who maintain long-term control on omalizumab including healthcare cost considerations.
View Article and Find Full Text PDF